Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:10 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-218156
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $$49,232 | 30,624 |
| General and administrative | 8,754 | 4,249 |
| Total operating expenses | 57,986 | 34,873 |
| Loss from operations | (57,986) | (34,873) |
| Other income: | ||
| Interest income | 4,776 | 4,524 |
| Other income (loss) | 121 | (40) |
Item 1. Financial Statements.
FAQ
- What is Olema Pharmaceuticals, Inc.'s R&D?
- Olema Pharmaceuticals, Inc. (OLMA) reported R&D of $49.23M in Q1 2026.
- How has Olema Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Olema Pharmaceuticals, Inc.'s R&D increased by 60.8% year-over-year, from $30.62M to $49.23M.
- What is the long-term trend for Olema Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s R&D has grown at a 32.5% compound annual growth rate (CAGR), from $51.1M to $157.7M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Olema Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude